Key result
Oral pancreatic kallikrein lowers blood pressure by ~13/12 mm Hg versus placebo in hypertension.
RCT (n=20)
Double-blind
Answers are grounded in this paper and cite their sources.
The antihypertensive effect of oral administration of pig pancreatic kallikrein was investigated in a double blind study of 20 patients with essential hypertension. Kallikrein treatment lowered the blood pressure (BP) significantly from 159.5/104.5 to 146.3/92.8 mm Hg in the supine and from 153/106.1 to 136.1/95.6 mm Hg in the standing position. Blood pressure remained unchanged in the placebo group. Urinary kallikrein, sodium excretion, and GFR increased with treatment, but these changes did not reach statistical significance, In the kallikrein-treated patients but not in the placebo group, urinary kallikrein was correlated both to GFR (r = 0.7, p less than 0.001) and sodium excretion (r = 0.5, p less than 0.01). The antihypertensive mechanism of kallikrein treatment remains unknown. It could be speculated that kallikrein may induce changes in local blood flow, mediated by kinin and prostaglandin release.
No takes yet. Share an insight, caveat, or question.
Overlack et al. (1981) conducted an RCT in Essential hypertension (n=20). Oral pig pancreatic kallikrein vs. Placebo was evaluated on Blood pressure (supine and standing). Oral pig pancreatic kallikrein significantly lowered supine BP from 159.5/104.5 to 146.3/92.8 mm Hg and standing BP from 153/106.1 to 136.1/95.6 mm Hg, vs no change with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: